⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Triumph Research Intelligence (TRI) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Triumph Research Intelligence (TRI)
↗Cambridge, United Kingdom
Triumph Research Intelligence (TRI) is a specialized technology provider focused on Risk-Based Quality Management (RBQM) solutions for the clinical trials industry. The company provides a unified platform, OPRA, which includes modules for centralized monitoring (OPRA-CM), risk assessment and management (OPRA-RAM), and subject-level monitoring (OPRA-SM).
TRI serves pharmaceutical companies and Contract Research Organizations (CROs) by helping them streamline clinical trial oversight, automate manual tasks, and ensure compliance with regulatory standards such as ICH E6 (R3). The company is known for its focus on data-driven decision-making, aiming to improve trial efficiency, data quality, and patient safety.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:-
Industry:Digital Health
Sub-Industry:Clinical Trial Management Software / RBQM
SIZE & FINANCIALS
Employees:51-200
Founded:2013
Ownership:private
Status:operating
FUNDING
Stage:Growth Stage
Investors:Octopus Investments
0
CORPORATE STRUCTURE
Key Partnerships:Worldwide Clinical Trials (Strategic partnership for RBQM technology deployment)
COMPETITION
Position:Niche Player
Competitors:Biorce, Other clinical trial monitoring software providers
LEADERSHIP
Key Executives:
Duncan Hall - CEO
LINKS
Website:tritrials.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Triumph Research Intelligence (TRI). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.